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MKK3 and MKK4 cDNAs labeled by random priming 
with Ja-32PJdATP (deoxyadenosine triphosphate) 
(Amersham International PLC).
26. GST-ATF2, GST-c-Jun, GST-JNK1, and GST- 
ERK2 have been described (4, 19, 20). GST-p38 
MAP kinase was prepared from the expression 
vector pGSTag [H. Dressier et a/., Biotechniques 
13, 866 (1992)] and a PCR fragment containing the 
coding region of the p38 MAP kinase cDNA. GST- 
MKK3 and GST-MKK4 were prepared with pGEX- 
3X (Pharmacia-LKB Biotechnology) and PCR frag­
ments containing the coding region of the 
MKK3 and MKK4 cDNAs. The GST fusion proteins 
were purified by affinity chromatography with the 
use of GSH-agarose [S. B. Smith and K, S. John- 
son, Gene 67, 31 (1988)]. The expression vectors 
pCMV-Flag-JNK1 and pCMV-MEK1 have been de­
scribed (4, 20). The plasmid pCMV-Flag-p38 MAP 
kinase was prepared with the expression vector 
pCMV5 [S. Andersson, D, L. Davis, H. Dahlback, H. 
Jornvall, D. W. Russell, J. Biol. Chem, 264, 8222
(1989)] and the p38 MAP kinase cDNA. The ex­
pression vectors for MKK3 and MKK4 were pre­
pared by subcloning of the cDNAs into the 
polylinker of pCDNA3 (Invitrogen). The Flag epitope 
(-Asp-Tyr-Lys-Asp-Asp-Asp-Aps-Lys-; Immunex, 
Seattle, WA) was inserted between codons 1 and 2 
of the kinases by insertional overlapping PCR [S. N. 
Ho, H. D. Hunt, R. M. Horton, J. K, Pullen, L. R. 
Pease, Gene 77, 51 (1989)1. A similar PCR proce­
dure was used to replace Thr180 and Tyrt82 of p38 
MAP kinase, and Thr183 and Tyr185 of JNK1, with 
Ala and Phe, respectively. The sequence of all plas­
mids was confirmed by automated sequencing on 
an Applied Biosystems model 373A machine.
27. COS-1 cells were maintained in Dulbecco’s modi­
fied Eagle’s medium supplemented with fetal bo­
vine serum (5%) (Gibco-BRL). The cells were trans­
fected with the lipofectamine reagent according to 
the manufacturer's recommendations (Gibco-BRL) 
and treated with UV radiation or EGF as described 
[4). The cells were solubilized with lysis buffer [20
mM tris (pH 7.4), i%  Triton X-100, 10% glycerol, 
137 mM NaCI, 2 mM EDTA, 25 mM p-glycerophos­
phate, 1 mM Na orthovanadate, 2 mM pyrophos­
phate, 1 mM phenylmethylsulfonyl fluoride, and 
leupeptin (10 n>g/m1)] and centrifuged at 100,000c/ 
for 15 min at 4°C. The epitope-tagged protein ki­
nases were immunopreclpitated by incubation for 1 
hour at 4°G with the M2 antibody (IBl-Kodak) 
bound to protein G-Sepharose (Pharmacia-LKB 
Biotechnology). The immunoprecipitates were 
washed twice with lysis buffer and twice with ki­
nase buffer (21).
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Association Between X-Linked Mixed Deafness 
and Mutations in the POU Domain Gene POU3F4
Yvette J. M. de Kok,* Silvere M. van der Maarel,*
Maria Bitner-Glindzicz, Irene Huber, Anthony P. Monaco, 
Susan Malcolm, Marcus E. Pembrey, Hans-Hilger Ropers,
Frans P. M. Cremerst
Deafness with fixation of the stapes (DFN3) is the most frequent X-linked form of hearing 
impairment The underlying gene has been localized to a 500-kilobase segment of the 
Xq21 band. Here, it is reported that a candidate gene for this disorder, Brain 4 (POU3F4), 
which encodes a transcription factor with a POU domain, maps to the same interval, in 
five unrelated patients with DFN3 but not in 50 normal controls, small mutations were 
found that result in truncation of the predicted protein or in nonconservative amino acid 
substitutions. These findings indicate that POU3F4 mutations are a molecular cause of 
DFN3.
öevere, inherited childhood deafness oc­
curs in about 1 out of 1 0 0 0  births and 
presents a serious worldwide public health 
problem (J). In 70% of these cases, deafness 
is not associated with other clinically rec­
ognizable features (2). To date, genes for 
nonsyndromic sensorineural deafness have 
been mapped to five different autosomes 
(3), but none o f  these has been isolated yet. 
T he most frequent cause of X-linked hear­
ing impairment, X-linked mixed deafness 
(DFN3) (McKusick catalog number 
304400), is characterized by a conductive
hearing loss that results from stapes fixation 
and progressive sensorineural deafness ( 4} 
5 ). However, a profound sensorineural deaf-
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ness sometimes masks the conductive ele­
ment (6 ). Computerized tomography (CT) 
studies in people with DFN3 demonstrated 
an abnormal dilatation of the internal 
acoustic canal (IAC) as well as an abnor­
mally wide communication between the
I A C  and the inner ear compartment (7). As 
a result, there is an increased perilymphatic 
pressure that is thought to underlie the 
observed “gusher” during the opening of 
the stapes footplate. The gene underlying 
DFK3 has been mapped to Xq21 by linkage 
analysis (8 ,9 )  and through molecular char­
acterization of large and submicroscopic de­
letions ( i 0 3 11), Yeast artificial chromo­
some (YAC) clones that span the critical 
region were isolated, and an 850-kb cosmid 
contig was constructed (12). This enabled 
us to identify and characterize two addition­
al microdeletions, as well as a 150-kb dupli­
cation in patients with DFN3, and to assign 
the gene underlying DFN3 to a 500-kb 
interval of Xq21.1 (12,  13) (Fig. IB).
Recently, the gene Brain 4 (Pou3f4),
which codes for a transcription factor, was 
mapped between the proteolipid protein lo­
cus Pip and the DXMit6  marker near the 
phosphoglycerate kinase 1 (Pg/<J) gene on 
the murine X chromosome (14). The chro­
mosomal region between Pghl and Pip is 
evolutionary conserved between humans 
and mice, which suggests that the human 
POU3F4  gene is located in the XqI3-q22
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Fig. 1. Localization of the human POU3F4 gene. (A) Southern blot analysis with the use of a mouse 
Pou3f4 probe and a control probe, 8-aminolevulinate synthetase (ALAS2), with genomic DNAs from a 
control male, D20, and TD (76). Patient D20 has choroideremia (CHM), mental retardation (MR), and 
X-linked mixed deafness (DFN3); patient TD shows evidence of DFN3 (12). (B) Physical map of the DFN3 
critical region. All patients with deletions have been described elsewhere (72), Patient 5086 carries a 
150-kb duplication spanning DXS26. The extent of the cosmid contig is given at the bottom. POU3F4 is 
located on cosmids IC2 (lCRFc104L0131) and IC3 (ICRFc104B1939), approximately 20 kb distal to 
DXS995 (72). Restriction mapping of the cosmid containing the POU3F4 gene indicated that the POU3F4 
gene is oriented with its 5' end toward the centromere.
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interval. The rat homo log of POU3F4, 
RHS2, is expressed during embryonic devel­
opment in the brain, the neuraL tube, and
the otic vesicle at 15.5 and 17.5 days after 
conception (15).
Thus, both its map position and its tem­
poral and spatial expression pattern in early
embryogenesis rendered POU3F4 an attrac­
tive candidate gene for DFN3. To confirm 
and refine the localization of the human 
POU3F4 gene, we amplified a murine 
genomic Pou3f4 gene fragment by poly­
merase chain reaction (PCR) and hybrid­
ized it to Southern (DNA) blots containing 
Eco Rl-digested D N A  from patients with 
Xq21 deletions {16).  A  12-kb Eco RI frag­
ment was seen in the male control but not 
in the DFN3 patients TD and D20 who 
carry variably sized deletions in Xq21 (Fig. 
1 A). The deletions overlap in a small chro­
mosomal segment encompassing DXS995
(Fig. IB), which positions the POU3F4
gene in a 1 2 0 -kb region of the previously 
constructed 850-kb cosmid contig that 
spans the DFN3 locus. By hybridizing the 
Pou3f4 probe to cosmids from this contig, 
we could localize the POU3F4 gene 20 kb 
distal to DXS995 (Fig. IB).
We used PCR primers complementary 
to the murine Pou3f4 gene sequences to 
amplify a human POU3F4  fragment from 
cosmid DNA, which was then used as a 
probe to screen a human fetal brain com­
plementary DNA  (cD N A ) library (17). 
Six overlapping cDNAs were identified 
and partially characterized. In total, we
isolated 1.4 kb of the human POU3F4
cDNA sequence, which contained the 
complete protein coding region of 1083 
base pairs as inferred from the rat RHS2 
and mouse Pou3f4 sequences (15, 18, 19) 
(Fig. 2 ). The rat and mouse proteins are 
completely identical, and the human pro­
tein contains only four conservative ami­
no acid substitutions (Fig. 2).
To search for mutations in the POU3F4 
gene, we examined DNA from 14 unrelated 
patients with X-linked deafness and 50 un­
related control females from different eth­
nic origins for single-strand conformation
(SSC) variants (20). Because the POU3F4
gene contains no introns, five different 
PCR primer sets were sufficient to span the 
entire coding region of POU3F4. Six of the 
deafness patients (Table 1) had character­
istic features of DFN3— that is, a bony de­
fect observed during CT scanning or a peri­
lymphatic gusher encountered upon stape­
dectomy (4—7), In one case (patient 5823), 
audiologic data were consistent with a pro­
gressive mixed type of deafness, but neither 
CT scan nor stapes surgery were performed. 
SSC shifts indicative of sequence alter­
ations were found in four DFN3 patients, 
two of which are shown in Fig. 3A, but not 
in the 50 control females.
Subsequently, we sequenced the protein 
coding region of the POU3F4 gene in all 
patients with X-linked hearing impairment. 
In all four patients with SSC shifts as well as 
in patient 5823, who was not studied by
PCR-SSC analysis, mutations were observed 
in the POU3F4  gene. In three DFN3 pa­
tients, we found small deletions in the 
POU-specific and POU homeodomains of 
























ATG GIX  ACA GCT GCC TCG AAT CCC 7 AC AGC ATT CTC ACT TCC ACC TCC CTA GTC CAT GCG G AC TCT GCG GGC ATG 
M A  T A A ' S N P  Y S I L S S T  S L V H A D S A G H 25
________ Lta_______ \
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Fig. 2. Nucleotide sequence and the deduced amino acid sequence encoded by human POU3F4 {21). 
The oligonucleotides used for PGR-SSC analysis are indicated with arrows. The POU-specific and POU 
homeodomains are boxed. The human POU3F4 protein is identical to the protein in mice and rats, except 
for the following conservative amino acid changes from humans to rats and mice: T15S, P122S, A159T, 
and T356A. The nucleotide changes and deletions (A) in the DFN3 patients are indicated; affected 
nucleotides are marked with a bar. The asterisk indicates a stop codon.
Table 1. Clinical features and POU3F4 mutations of patients with X-linked deafness (21). The deafness 
type here is based on audiologic examination. The POU3F4 mutations are named “ stop” according to 
the Jast wild-type amino acid that remains in the predicted protein. Blank spaces indicate that no CT scan 









2412 Yes Mixed — (29)
2540 Yes Yes Mixed — (5)
3055 Yes Mixed L298 stop (30)
3105 Yes Yes Mixed D215 stop (30)
5274 Yes Sensorineural K202 stop (9)
5736 Yes Mixed L317W (9)
5823* Mixed K334E (30)
2418 • Sensorineural — (30)
2964 Sensorineural — (30) ■
3036 Sensorineural — (30)
3056 - No Sensorineural — (30)
5106 No Sensorineural — (9)
5347 No Sensorineural — (9)
5943 No . Sensorineural — (9)
2266 Conductive — (30)
Some DFN3-affected maternal relatives of patient 5823 also have cataracts at a young age.
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premature stops of translation (Table 1 and
Fig. 2 ). Patient 3055 carries a deletion of an 
A nucleotide at position 895 (Figs. 2 and 
3C)> patient 3105 has a deletion of one G 
that is part o f a GGGG tetranucleotide 
stretch at positions 648 to 651, and in pa­
tient 5274 a C A A A  tetranucleotide is delet­
ed that is present in tandem at positions 603 
to 610 of the wild-type POU3F4  sequence. 
As shown in Fig. 3B by SSC analysis, the 
mutation found in patient 5274 cosegregates 
with the DFN3 phenotype in the whole 
family. Two patients had missense mutations
in the POU3F4  gene. In patient 5736, we
found a T to G  tr ans vers ion at position 950, 
whereas patient 5823 showed an A  to G 
transition at nucleotide 1000. These muta­
tions result in  the nonconservative L317W 
and K334E substitutions in the POU home-
odomain (21 ).
The leucine residue at position 317 that 
is mutated in patient 5736 is located be­
tween helices 2 and 3 of the POU homeo- 
domain, as deduced from nuclear magnetic
resonance and crystallographic studies (2 2 ). 
It is conserved in six of seven members of 
the non-POU domain proteins that belong 
to the homeodomain superfamily (23) and 
in all POU domain proteins, except Oct-2 
and emb. Here, the leucine residue is sub­
stituted for a methionine and a tyrosine 
residue, respectively (24). The wild-type ly­
sine residue at position 334 that is mutated 
in patient 5823 resides in helix 3 of the 
POU homeodomain. This residue is con­
served among all POU domain proteins and 
members of the homeodomain superfamily
(23, 24) and contacts the DNA backbone 
in the major groove in the proposed crystal 
structure of the engrailed homeodomain- 
DNA complex, but not in the Oct-1 POU 
domain-octamer complex (22, 25). Thus, 
these data strongly suggest that all muta­
tions we observed in the POU3F4 gene are 
clinically relevant and give rise to DFN3. 
Because DFN3 is a rare disorder, the total 
number of DFN3 patients that can be in­
vestigated will remain limited. Neverthe-
A
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Fig. 3. Mutation analysis of POU3F4. (A) PCR-SSC analysis of the homeodomain of POU3F4 In 14 
patients with X-linked deafness and a male control (46, XY) with the use of the primer set V (20), The 
observed SSC shifts are indicated by arrows. (B) PCR-SSC analysis of the DFN3 family of patient 5274 
(indicated by an arrow) with the use of primer set IV. Obligate carrier females are marked as such in the 
pedigree (circles with dots). DFN3 patients are indicated with solid squares; symbols with lines designate 
deceased individuals. The asterisk indicates the presence of a weak wild-type (WT) SSC band in lane 12, 
Of the four females at risk of carrying the CAAA deletion, individual 10 carries the wild-type POU3F4 
sequence, whereas individuals 7, 13, and 18 carry the mutation. (C) Nucleotide (nt) sequence of part of 
the POU homeodomain of patient 3055 and a control male.
less, the identification of five mutations in 
seven DFN3 patients as compared to no 
single mutation in 100 control X chromo­
somes is statistically highly significant (26).
Unexpectedly, three Xq21 microdeie- 
tions (G 8314, II/7, and 1/ 1 0 ) and one du­
plication (in patient 5086) that had been 
identified previously in patients with DFN3 
do not encompass the POU3F4 gene. In all 
four cases, the rearrangement is located 
proximal and 5' to POU3F4 , with physical 
distances varying between 15 and 400 kb 
(Fig. IB). In none of these patients, nor in 
two others with either a perilymphatic 
gusher during stapes surgery or a temporaL 
bone defect (patients 2412 and 2540), were 
point mutations detected in the POU3F4 
gene. Thus, in these cases DFN3 may be 
caused by mutations that affect 5' noncod­
ing or regulatory sequences mapping farther 
upstream. Alternatively, these aberrations 
may affect the gross chromosomal structure 
and thus may affect expression of POU3F4. 
Another, less likely explanation might be 
the presence of other genes in Xq21.1 that 
can cause DFN3.
In seven patients with X-linked sensori­
neural deafness and in one with X-linked 
conductive deafness, mutations were not 
found in the POU3F4 gene. This is not
surprising because previous linkage studies 
had indicated that X-linked deafness is het­
erogeneous. In at least one family with sen­
sorineural deafness, the defect has been ex­
cluded from Xq21 (9). In two other fami­
lies, linkage to the Xq21 and X pll.3-p21,l 
regions has been found (27). Here, we dem­
onstrate that DFN3 is correlated with mu­
tations that affect the POU3F4 protein. At 
least five POU domain genes are expressed 
in different parts of the developing inner 
ear (28), and defects of POU domain genes 
may play a major role in the etiology of 
nonsyndromic hearing impairment.
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1  he three major muscle cell types (skeletal, 
cardiac, and smooth) express many of the 
same muscle-specific genes* which suggests 
that they may use a common myogenic reg­
ulatory program that directs muscle gene 
transcription. However, each muscle cell 
type is unique with respect to the muscle 
proteins expressed, contractile properties, 
ability to divide, and morphology. Thus, if a 
common myogenic program exists, it must 
be modified by additional regulatory factors 
to generate muscle cell diversity.
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In vertebrates, skeletal muscle formation 
is controlled by a family of myogenic basic 
helix-loop-helix (bHLH) proteins, w hich  
includes MyoD, myogenin, myf5, and 
MRF4 [reviewed in (J)]. When expressed 
ectopically in nonmuscle cell types, these 
factors can activate skeletal muscle gene  
expression* The myogenic bHLH factors are 
exclusively expressed in skeletal muscle. 
Therefore, other regulators must control 
muscle gene expression in cardiac and 
smooth muscle. MEF2, which recognizes an  
A-T-rich DNA sequence associated w ith  
skeletal, cardiac, and smooth muscle genes, 
may be such a factor (2). Four mef'2 gen.es, 
designated me/2 a, -b, -c, and -d, have been  
cloned from several vertebrate species (3 , 
4). MEF2 factors, also known as related to  
serum response factors (RSRFs) (4), belong  
to the MADS family of transcription factors
Requirement of MADS Domain Transcription
Factor D-MEF2 for Muscle Formation
in Drosophila
Brenda Lilly, Bin Zhao, Gogineni Ranganayakulu,
Bruce M. Paterson, Robert A. Schulz, Eric N. Olson*
Members of the myocyte enhancer binding factor-2 (MEF2) family of MADS (MCM1, 
agamous, deficiens, and serum response factor) box transcription factors are expressed 
in the skeletal, cardiac, and smooth muscle lineages of vertebrate and Drosophila em­
bryos. These factors bind an adenine-thymidine-rich DNA sequence associated with 
muscle-specific genes. The function of MEF2 was determined by generating a loss-of- 
function of the single mef2 gene in Drosophila (D-mef2). In loss-of-function embryos, 
somatic, cardiac, and visceral muscle ceils did not differentiate, but myoblasts were 
normally specified and positioned. These results demonstrate that different muscle cell 
types share a common myogenic differentiation program controlled by MEF2.
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